Dudediligence.

Amylyx Pharmaceuticals, Inc

AMLXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$416,000Sep ’24−$665,000Dec ’24$0.00Mar ’25$0.00Jun ’25$0.00Sep ’25$0.00Dec ’25
Net income, by quarter
−$72.7MSep ’24−$37.5MDec ’24−$35.9MMar ’25−$41.4MJun ’25−$34.4MSep ’25−$33.0MDec ’25−$41.3MMar ’26−$43.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$285,000$22.2M$380.8M$87.4M$0.00
Gross profitnone on file$19.2M$355.3M$81.4M$0.00
Operating income−$82.7M−$201.3M$38.8M−$314.7M−$153.3M
Net income−$87.9M−$198.4M$49.3M−$301.7M−$144.7M
Operating cash flow−$74.8M−$179.9M$11.9M−$167.6M−$123.3M
Free cash flow−$75.2M−$182.4M$10.7M−$167.8M−$123.5M
Cash$50.2M$62.5M$170.2M$77.4M$226.7M
Shares outstanding7.0M66.5M67.7M68.6M109.9M